Published in the Journal for ImmunoTherapy of Cancer (JITC), is a research article detailing how the University of Pittsburgh Cancer Institute implemented a protocol for the administration of HD IL-2 in a non-ICU oncology specialty setting in 1994. To provide estimates of the toxicity and efficacy of this method of administration, they conducted a retrospective analysis of response, survival and toxicity data of 243 advanced melanoma patients treated with HD IL-2 between 1992 and 2015.
Authors: Diwakar Davar, Fei Ding, Melissa Saul, Cindy Sander, Ahmad A. Tarhini, John M. Kirkwood and Hussein A. Tawbi
JITC(2017) 5:74#2017 #JITCPublication #Researcher #SkinCancer #Cytokines #ImmuneCheckpointInhibitors #Article #Advanced #Biomarkers
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com